New heart pump could be lifeline for failing hearts
NCT ID NCT05876000
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new mechanical heart pump, called the Corheart 6, in 53 people with advanced heart failure. The pump is implanted to help the heart pump blood. Researchers want to see if it is safe and effective at keeping patients alive, either until they can get a heart transplant or while living with the device. The main goal is to see how well patients do 6 months after the pump is placed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Corheart 6 Left Ventricular Assist System (a mechanical heart pump)
- What this could lead to
- If successful, this device could offer a new option for people with severe heart failure, helping them live longer or survive until a heart transplant.
- What could go wrong
- This is a small, early-stage study with only 53 participants, so results may not apply to everyone. The device carries risks like stroke, infection, or pump failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 53 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2024
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Age ≥ 18 years and ≤ 75 years * 2\. The patient has signed an Informed Consent Form * 3\. Body Surface Area (BSA) ≥ 1.2 m\^2 * 4\. New York Heart Association (NYHA) Class IV * 5\. Left Ventricular Ejection Fraction (LVEF) ≤ 25% * 6\. Despite the optimal medical management based on current guidelines, the patient must also meet one or more of the following: * a. Unable to exercise for HF, * or * if able to perform cardiopulmonary testing, with peak VO2 \<12 mL/kg/min and/or \< 50% predicted value; * b. Progressive end-organ dysfunction (worsening renal and/or hepatic function, type II pulmonary hypertension, cardiac cachexia) due to reduced perfusion and not to inadequately low ventricular filling pressure (PCWP \> 20 mmHg and SBP \< 90 mmHg or CI \< 2.0 L/min/m2). * c. Impella or IABP assisted; * d. Inotrope dependent/unable to wean from inotropes. Exclusion Criteria: * 1\. Heart failure who can be treated with other therapy options (e.g. CRT, CRT-D, etc.) * 2\. Intolerance to anticoagulant or antiplatelet therapies or any other peri/post-operative therapy the investigator will require based upon the patients' health status. * 3\. Patient has known hypo or hyper coagulable states such as disseminated intravascular coagulation and heparin induced thrombocytopenia type II. * 4\. Platelet count \< 100,000 x 10\^3/L (\< 100,000/ml). * 5\. Psychiatric disease/ disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and ventricular assist system management. * 6\. Technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator. * 7\. Presence of an active, uncontrolled infection. * 8\. Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure: * a. Total bilirubin \> 51.3 μmol/L (3.0 mg/dl), ischemic hepatitis, or biopsy proven liver cirrhosis, or clinically Child-Pugh B and C score. * b. History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1/FVC \< 0.7, or FEV1 \< 50% predicted. * c. Fixed pulmonary hypertension with a most recent PVR ≥ 8 Wood units that is unresponsive to pharmacologic intervention. * d. History of stroke within 180 days prior to enrollment, or a history of cerebrovascular disease with symptomatic (\> 70%) carotid artery stenosis * e. Serum creatinine ≥ 265 μmol/L (3.0mg/dl) or requiring dialysis. * f. Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration. * 9\. Etiology of heart failure (HF) due to or associated with uncorrected thyroid disease, obstructive/ restrictive cardiomyopathy, pericardial disease, amyloidosis or giant cell myocarditis. * 10\. Uncorrected moderate to severe aortic insufficiency without plans for correction during pump implant. * 11\. History of confirmed, untreated abdominal aortic aneurysm (AAA) or thoracic aortic aneurysm (TAA) \> 5 cm in diameter. * 12\. Uncontrollable ventricular tachyarrythmias/ ventricular fibrillation (VF). * 13\. STEMI \<2 weeks before planned implantation. * 14\. Right ventricular failure as defined by one or more of the following: * a. severe depressed RV function in echocardiography * b. TAPSE \< 1.0 cm * c. CVP/PCWP ratio \> 0.63 * 15\. Planned Bi-VAD support prior to enrollment. * 16\. Cardiac arrest with a history of resuscitation 1-month before inclusion, without full restoration of cognitive function. * 17\. History of any organ transplant. * 18\. Pre albumin \< 150 mg/L, or Albumin \< 30g/L (3 g/dL). * 19\. Any condition other than HF that could limit survival to less than 24 months. * 20\. Positive pregnancy test if of childbearing potential. * 21\. Lactating mothers. * 22\. Participation in any other clinical investigation that is likely to confound study results or affect the study. * 23\. Patients who have been placed in an institution by court order or by order of the authorities.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced left ventricular heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
11 sites in 3 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
NOT_YET_RECRUITINGTorino, Italy
-
Deutsches Herzzentrum der Charité
RECRUITINGBerlin, Germany
-
Herz-und Diabeteszentrum Nordrhein-Westfalen
RECRUITINGBad Oeynhausen, Germany
-
Herzzentrum Leipzig
RECRUITINGLeipzig, Germany
-
IRCCS Ospedale San Raffaele
NOT_YET_RECRUITINGMilan, Italy
-
Klinikum Links der Weser
NOT_YET_RECRUITINGBremen, Germany
-
Universitätskliniken der MedUni Wien
RECRUITINGVienna, Austria
-
Universitätsklinikum Graz
NOT_YET_RECRUITINGGraz, Austria
-
Universitätsklinikum Hamburg
RECRUITINGHamburg, Germany
-
Universitätsklinikum Würzburg
NOT_YET_RECRUITINGWürzburg, Germany
-
Universitätsklinikums Heidelberg
RECRUITINGHeidelberg, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.